Infinity Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Infinity Pharmaceuticals's earnings have been declining at an average annual rate of -14.5%, while the Biotechs industry saw earnings growing at 15.8% annually. Revenues have been declining at an average rate of 54% per year.
Key information
-14.5%
Earnings growth rate
-2.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -54.0% |
Return on equity | n/a |
Net Margin | -1,593.9% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
Nov 10Infinity Pharmaceuticals: Waiting For A Deal
Sep 08Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?
May 23We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely
Dec 29Investigating Infinity Pharmaceuticals
Nov 25Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans
Jul 18Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now
Jun 03Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?
Apr 13Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?
Feb 19Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?
Jan 15Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer
Jan 06Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?
Dec 11Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium
Dec 09Infinity Pharmaceutical Reaching Vital New Staging Posts
Dec 01Revenue & Expenses Breakdown
How Infinity Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 3 | -41 | 14 | 0 |
31 Mar 23 | 3 | -43 | 16 | 0 |
31 Dec 22 | 3 | -44 | 13 | 0 |
30 Sep 22 | 3 | -47 | 14 | 0 |
30 Jun 22 | 2 | -47 | 14 | 0 |
31 Mar 22 | 2 | -46 | 14 | 0 |
31 Dec 21 | 2 | -45 | 14 | 0 |
30 Sep 21 | 2 | -44 | 14 | 0 |
30 Jun 21 | 2 | -43 | 13 | 0 |
31 Mar 21 | 2 | -41 | 13 | 0 |
31 Dec 20 | 2 | -40 | 12 | 0 |
30 Sep 20 | 2 | -41 | 13 | 0 |
30 Jun 20 | 1 | -43 | 13 | 0 |
31 Mar 20 | 1 | -44 | 14 | 0 |
31 Dec 19 | 3 | -47 | 14 | 0 |
30 Sep 19 | 3 | -44 | 15 | 0 |
30 Jun 19 | 25 | -19 | 14 | 0 |
31 Mar 19 | 24 | -16 | 14 | 0 |
31 Dec 18 | 22 | -11 | 14 | 0 |
30 Sep 18 | 22 | -10 | 15 | 0 |
30 Jun 18 | 6 | -31 | 16 | 0 |
31 Mar 18 | 6 | -41 | 19 | 0 |
31 Dec 17 | 6 | -42 | 22 | 0 |
30 Sep 17 | 6 | -57 | 24 | 0 |
30 Jun 17 | 0 | -70 | 25 | 0 |
31 Mar 17 | 9 | 0 | 30 | 0 |
31 Dec 16 | 19 | -30 | 35 | 0 |
30 Sep 16 | 28 | -46 | 37 | 0 |
30 Jun 16 | 119 | 15 | 41 | 0 |
31 Mar 16 | 114 | -76 | 39 | 0 |
31 Dec 15 | 109 | -128 | 37 | 0 |
30 Sep 15 | 104 | -129 | 35 | 0 |
30 Jun 15 | 174 | -71 | 33 | 0 |
31 Mar 15 | 169 | -68 | 31 | 0 |
31 Dec 14 | 165 | -17 | 29 | 0 |
30 Sep 14 | 161 | -10 | 28 | 100 |
30 Jun 14 | 0 | -145 | 28 | 100 |
31 Mar 14 | 0 | -142 | 27 | 100 |
31 Dec 13 | 0 | -127 | 28 | 0 |
30 Sep 13 | 0 | -141 | 27 | 74 |
30 Jun 13 | 0 | -88 | 26 | 74 |
31 Mar 13 | 22 | -71 | 27 | 74 |
Quality Earnings: INFI.Q is currently unprofitable.
Growing Profit Margin: INFI.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INFI.Q is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.
Accelerating Growth: Unable to compare INFI.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INFI.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: INFI.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.